BioMed Research International / 2015 / Article / Tab 1

Research Article

Bladder Carcinoma Data with Clinical Risk Factors and Molecular Markers: A Cluster Analysis

Table 1

Variables measured and available in the dataset.

NameDescriptionValuesSignificance

TypeType of sample1/2/3NMIBC/MIBC/control
AgeDiagnosis ageNumericYears
N HistoryIdentification numberNumeric
GenderGender1/2Male/female
FdiagnDiagnostic dataDateDD/MM/YYYY
TobaccoTobacco smoking0/1No/yes
AlcoholAlcohol consumption0/1No/yes
AfFamily history of BC0/1No/yes
Mfum More than 20 cigarettes a day0/1No/yes
OtrosfOther risk factors of BCTextNot analyzable
HematuriHaematuria0/1No/yes
IrritatIrritative syndrome0/1No/yes
DolorsupSuprapubic pain0/1No/yes
OtrosOther symptoms0/1No/yes
DiagnDiagnostic type1/2Symptomatic/incidental
Tumor Number of tumorsNumericNumeric
CreatCreatinineNumericmg/dL
GotGOTNumericU/L
GptGPTNumericU/L
HemNumber of red blood cellsNumericE6/uL
HbHaemoglobinNumericg/dL
HctoHematocritNumeric%
CaCalciumNumericmg/dL
PPhosphorumNumericmg/dL
FalcAlcaline phosphataseNumericU/L
Citesp, Citarr; eco, UIV; CT, cistoscDiagnosis test performedTextNot analyzable
MultipleMultiplicity1/2Single/multiple
TamSize (cm)numericcm
TAM3CMSize ≥3 cm1/2No/yes
AspectEndoscopic aspect1/2/31 Superficial/2 infiltrative/3 intermediate
ASPESUPSuperficial aspect1/2Yes/no
TtoType of adjuvant therapyTextNot analyzable
ADYUVAdjuvant therapy1/2Yes/no
JewettHistologic staging1/2/3A/B/C-D
GGrade1/2/3G1/G2/G3
G23 Grades 2 or 31/2No/yes
TnmTNM1/2Ta/T1
GriesEORTC risk group1/2Low-intermediate/high
GrxMillan risk group1/2Low-intermediate/high
AP, tipoAPType of BC1/2/9Not analyzable TCC/SC/other
p53ihaP53 immunohistochemistry1/2/3+/++/+++
p53riaP53 quantifiedNumericng/ml
NeuProt p185 quantifiedNumericHNU (0.05 fmol/mg)/ml
p16Prot p16 immunohistochemistry1/2/3+/++/+++
RecidRelapse1/2Yes/no
FechareFirst relapse dataDateDD/MM/YYYY
narecidNumber of relapsesNumericNumber
narecidpNumber of relapses till progressionNumericNumber
ProgProgression1/2Yes/no
FprogProgression dateDateDD/MM/YYYY
MetasMetastatic disease1/2Yes/no
MuerteDeath1/2Yes/no
FechmuerteDate of deathDateDD/MM/YYYY
MporcaCancer specific mortality1/2Yes/no
RecmNumber of relapses till deathNumericNumber
fechaultreLast Revision DateDateDD/MM/YYYY
EgfrEGFR quantifiedNumericEGFR fmol/protein mg
LogneuNeu logarithmNumericNumber of months
SuperSurvival (months)NumericNumber of months
IleRelapse-free survivalMonthsNumber of months
TprogreProgression-free survivalMonthsNumber of months
TmetasMetastatic disease-free survivalMonthsNumber of months
Np53riap53 RIATertile1/2/3Tertile 1/tertile 2/tertile 3
NneuNeuTertile1/2/3Tertile 1/tertile 2/tertile 3
NegfrEGFRTertile1/2/3Tertile 1/tertile 2/tertile 3
FiltroNMIBC
edad70Older than 70 years1/2Yes/no

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.